Head-to-head comparisons of medication uses, side effects, warnings, and more.
Biktarvy
Symtuza
Biktarvy
Symtuza
Summary of Biktarvy vs. Symtuza
Summary for HIV ARV Combo
Prescription only
Biktarvy is a combination antiretroviral that contains bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF). It's a complete antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV) infections in adults and children who weigh at least 30 pounds. Biktarvy isn't used for HIV pre-exposure prophylaxis (PrEP), but it is a first-choice option for people starting HIV treatment. Typically, this medication is taken by mouth once daily. Biktarvy doesn't commonly cause weight gain, but it can cause other side effects, such as nausea, diarrhea, and headache.
Summary for HIV ARV
Prescription only
Symtuza is a combination medication that treats human immunodeficiency virus (HIV). It's a tablet that contains three antiretroviral (ARV) medications — darunavir, emtricitabine, and tenofovir alafenamide — and a "booster" that helps the ARVs work better against the virus called cobicistat . Symtuza, also known as DRV/c/TAF/FTC, is a complete therapy for people with HIV weighing at least 88 pounds. It's taken once daily with food. Some common side effects of Symtuza include nausea and diarrhea.
Indications of Biktarvy vs. Symtuza
Indications for
Treatment of HIV infection in adults and children weighing at least 30 lbs, and:
•Starting HIV treatment for the first time, or
•HIV viral load hasn't been fully controlled with previous ART, and don't have resistance to certain medications
•Have a HIV viral load of less than 50 copies/mL from a previous ART